Lilly and Ypsomed collaborate to advance an automated insulin delivery system
INDIANAPOLIS — Eli Lilly and Co. and Ypsomed announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly’s connected diabetes solutions. Under the terms of the agreement, Lilly will commercialize the system, which is currently in development and will include an insulin pump developed and manufactured by Ypsomed.
